# Table of Contents

## Highlights of This Issue 3359

### SPECIAL FEATURES

#### CCR Translations

- **3361** MET as a Target in Papillary Renal Cell Carcinoma  
  André P. Fay, Sabina Signoretti, and Toni K. Choueiri  
  See related article, p. 3411

#### CCR Perspectives in Drug Approval

- **3364** U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009  
  Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

#### Statistics in Clinical Cancer Research

- **3371** Blocking and Randomization to Improve Molecular Biomarker Discovery  
  Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

#### Molecular Pathways

- **3379** Molecular Pathways: CDK4 Inhibitors for Cancer Therapy  
  Mark A. Dickson
- **3384** Molecular Pathways: Niches in Metastatic Dormancy  
  Kenji Yamoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

#### Review

- **3390** Infusions of Allogeneic Natural Killer Cells as Cancer Therapy  
  Wing Leung

## HUMAN CANCER BIOLOGY

- **3401** Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions  
  Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

- **3411** MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of PRCC with CGH Array and Matching Gene Expression Array  
  Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Campano, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
  See related article, p. 3361

- **3422** Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer  
  Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Offringa, Jens Werner, and Eduard Ryschich

- **3434** Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer  
  Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

## CANCER THERAPY: PRECLINICAL

- **3446** Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma  
  Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thienle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3458</td>
<td>Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)</td>
<td>Alba Matas-Cespedes, Vanina Rodriguez, Susana G. Kalko, Anna Vidal-Crespo, Laia Rosich,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Teresa Caserrats, Patricia Balsas, Neus Villamor, Eva Giné, Elías Campo, Gaël Roué,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Armando López-Guillermo, Dolors Colomer, and Patricia Pérez-Galán</td>
</tr>
<tr>
<td>3472</td>
<td>Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis</td>
<td>Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang</td>
</tr>
<tr>
<td>3485</td>
<td>Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells</td>
<td>Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser</td>
</tr>
<tr>
<td>3496</td>
<td>Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage</td>
<td>Giannaria Liccardi, John A. Hartley, and Daniel Hochhauser</td>
</tr>
<tr>
<td>3521</td>
<td>Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity</td>
<td>Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong</td>
</tr>
<tr>
<td>3531</td>
<td>In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment</td>
<td>Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafał Zielinski, Jacek Capala, and Amir Gándjábkhche</td>
</tr>
<tr>
<td>3550</td>
<td>Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy</td>
<td>Johannes Schwarzenberg, Johannes Czernin, Timothy F. Cloughesy, Benjamin M. Ellingson, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen</td>
</tr>
<tr>
<td>3560</td>
<td>Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm</td>
<td>Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persigehl, David P. Mozley, and Lawrence H. Schwartz</td>
</tr>
<tr>
<td>3581</td>
<td>A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer</td>
<td>Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eisys Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton</td>
</tr>
<tr>
<td>3589</td>
<td>Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML</td>
<td>Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herrndorfer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Streubeling, Matthias Mayerhofer, Thomas Kulicke, and Peter Valent</td>
</tr>
</tbody>
</table>

CANCER THERAPY: CLINICAL

3581 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eisys Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herrndorfer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Streubeling, Matthias Mayerhofer, Thomas Kulicke, and Peter Valent
3603  Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3613  Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamoto, Hideyuki Konishi, Tsukihisa Yoshida, Mitsushi Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

3623  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

LETTERS TO THE EDITOR

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.